Evidence for a two-stage disability progression in multiple sclerosis - Wikidata - wikimedia - TriplyDB

Evidence for a two-stage disability progression in multiple sclerosis

Evidence for a two-stage disability progression in multiple sclerosis

http://www.wikidata.org/entity/Q33944184

about

Rituximab for relapsing-remitting multiple sclerosis Rituximab for relapsing-remitting multiple sclerosis Optimizing treatment success in multiple sclerosis Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta New and emerging immune-targeted drugs for the treatment of multiple sclerosis The topographical model of multiple sclerosis: A dynamic visualization of disease course Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study iNKT Cells in Secondary Progressive Multiple Sclerosis Patients Display Pro-inflammatory Profiles.Central Atrophy Early in Multiple Sclerosis: Third Ventricle Volumetry versus Planimetry.Sound Lateralization Test Distinguishes Unimpaired MS Patients from Healthy Controls.Geographic variations of multiple sclerosis prevalence in France: The latitude gradient is not uniform depending on the socioeconomic status of the studied population.High resolution spectral domain optical coherence tomography (SD-OCT) in multiple sclerosis: the first follow up study over two years.Quantification of increased cellularity during inflammatory demyelination.The neuropathological basis of clinical progression in multiple sclerosis.Proteomic pattern analysis discriminates among multiple sclerosis-related disorders.Long term benefit of multiple sclerosis treatment: an investigation using a novel data collection technique.Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned.Palliative care for severely affected patients with multiple sclerosis: when and why? Results of a Delphi survey of health care professionals Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.Observational study assessing demographic, economic and clinical factors associated with access and utilization of health care services of patients with multiple sclerosis under treatment with interferon beta-1b (EXTAVIA).Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring.Relapses and disability accumulation in progressive multiple sclerosis Predictive value of imaging markers at multiple sclerosis disease onset based on gadolinium- and USPIO-enhanced MRI and machine learning.Age and disability accumulation in multiple sclerosis.Complement component C3 and butyrylcholinesterase activity are associated with neurodegeneration and clinical disability in multiple sclerosis.When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults?Predictors of chronic cerebrospinal venous insufficiency procedure use among older people with multiple sclerosis: a national case-control study.Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS Central Nervous System Idiopathic Inflammatory Demyelinating Disorders in South Americans: A Descriptive, Multicenter, Cross-Sectional Study The path to self-management: a qualitative study involving older people with multiple sclerosis.Detection of postural sway abnormalities by wireless inertial sensors in minimally disabled patients with multiple sclerosis: a case-control study.The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study.Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients Is Time to Reach EDSS 6.0 Faster in Patients with Late-Onset versus Young-Onset Multiple Sclerosis?Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple Sclerosis Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.The interactive web-based program MSmonitor for self-management and multidisciplinary care in multiple sclerosis: concept, content, and pilot results.Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system?

P2860

Q24234454-ED27F79D-66E2-4047-9DAC-83BA3EAD23E4 Q24234742-726FF852-EC12-4DEF-970C-7D75A0FB23B7 Q26771968-3B1EB32D-2002-4147-A9C4-FBF4C24030FA Q26864418-F1FE473B-ADB9-4986-B95F-91963907820D Q26997067-A45F9CEF-B870-4316-965A-D9CB58A41D67 Q27312133-E4BAF5B7-AC11-408E-BD6B-406C8ACFD0C5 Q28077000-FC9E7944-2B3D-4B1A-AAFC-13CB4389C2DA Q30000077-2DD71165-3632-4CC2-AF69-E001706CD7C8 Q30368046-4DEDC162-E9EE-476C-A44F-CA3B39CD0C47 Q30395772-2DE3CBCD-AE15-4609-8407-0CE12D0B192B Q30432891-8F85A495-515A-4A05-9ED6-33664A26EEC0 Q33692773-54163931-8F64-44CF-8293-2300D2BBF414 Q33911364-A824D329-677A-4D31-A9F9-2BEB187E150A Q34101668-D1ED6904-0CDF-4664-ABEF-EC41D6582F06 Q34188436-11A1B016-FEEB-4986-95DA-E030ED329D2D Q34241223-717EBB40-5BC0-4E35-AF2B-2BED75AC47FE Q34288517-22A6B2A6-91D6-47E5-A5D8-4D2B3B5940B2 Q34314312-2CA9E54F-1B3E-4E42-88F9-98BB15FE1EC3 Q34330516-701D2A46-3F5A-41F2-8014-7A5B5CAAAE83 Q34431275-A1D0A295-FC5E-4A66-A275-9D325E5C2B70 Q34566243-73715147-8AAC-4163-8CCC-683B0894505B Q35093103-19BFB22F-3AB7-4A56-9102-0C869753779C Q35106567-3DAEEE96-1EF7-4569-8E31-BE0E7C20191E Q35137514-9605620F-C07D-40F4-88A5-3DC63B18C221 Q35230950-E72F9BE7-8C20-4F3A-9D77-B69EA686467D Q35250966-E2C37D3C-F9CD-457E-85D1-DB0321043F2E Q35374052-CDB741DE-FCD6-4504-866A-0AFCC9BBCC1F Q35584048-DCA51285-1DF9-4AD7-9C7A-7FDB3F545073 Q35653675-F5EF9D34-642E-4F4F-B59F-3331574F214D Q35722940-06C6AB9F-E816-4DCA-9FB0-F69CEA96FE9E Q35760400-D1EB70F7-B915-4907-BFD6-4A5F83A506BB Q36015734-CB2EFBD2-0CA2-4C00-8E3B-4F995DD3B840 Q36062456-CE728C00-FB5E-454C-B1F7-0B6509D39336 Q36097847-4985BE6E-6E21-4FBF-BC21-4AF2162088DF Q36099150-C584AF90-BE36-4AA5-860C-A8136A3CA00D Q36179420-20333E35-924A-435F-ACA5-3052525FD5EB Q36247618-484EF8FF-BE17-486A-A805-7C71ABE44F7A Q36353053-26065889-35FD-46DC-A2BD-35FA0EDEFF77 Q36389736-3E7F9789-2C4B-4206-821A-BD00B788B1BA Q36432500-6A19828D-A8CF-4CCE-BAFB-DB0F55B46AF7

P2860

Evidence for a two-stage disability progression in multiple sclerosis

http://www.wikidata.org/entity/Q33944184

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Evidence for a two-stage disability progression in multiple sclerosis

@ast

Evidence for a two-stage disability progression in multiple sclerosis

@en

type

label

Evidence for a two-stage disability progression in multiple sclerosis

@ast

Evidence for a two-stage disability progression in multiple sclerosis

@en

prefLabel

Evidence for a two-stage disability progression in multiple sclerosis

@ast

Evidence for a two-stage disability progression in multiple sclerosis

@en

P1433

Q33944184-606ED2E0-C486-483B-B5C8-918B47B86702

P1476

Q33944184-EAAD7036-ED23-4B82-9EAA-A9127B9C78CC

P2093

Q33944184-006427BA-BA52-4FCD-98F4-54F4E899D883

Q33944184-1FF8C3DB-6227-402E-B9B2-512F09378632

Q33944184-25E4B0A6-DFFC-4446-B89A-89DD9689B523

Q33944184-2EC74E4F-275D-4E91-8236-0C9589DEAF45

Q33944184-372AE7F3-45BB-4D9C-B2CE-E675E5753F35

Q33944184-6515C6D6-2B41-451E-B0F8-2E485E9B8BB7

Q33944184-E4720A6F-C283-4EA4-BF0D-4C6382C980EB

P2860

Q33944184-03C4FA56-D91D-4455-88F7-087F46B9F189

Q33944184-0E08C381-4EFC-41FB-8C13-054D592420D2

Q33944184-1EE12FF4-719C-4411-9BC7-030052978ECF

Q33944184-1EEFB859-E40E-4DBE-8A66-B2926ECAA64B

Q33944184-25441477-8001-4995-9F46-35412167B67C

Q33944184-2631A7E3-C928-4800-82D1-1A530975E57C

Q33944184-2D1C4264-F345-4BE7-870A-8DA00B2A121B

Q33944184-46EA7B5A-E6E0-4BE9-A728-5E75925F7900

Q33944184-47B6050F-49FF-497A-A32A-27C4BBC4B90A

Q33944184-4AE0DCA4-991E-4219-A275-55E0546F465B

P304

Q33944184-9B1C90FD-F8B2-47DF-94D9-1FE85F831632

P31

Q33944184-862C2865-BF39-4EEF-AC58-78E8C17667E5

P356

Q33944184-838A99A5-8107-474C-AD5B-7B02FD57DF52

P407

Q33944184-16EF3ED0-4F37-4A67-928E-8CC9E14C5B75

P433

Q33944184-A224CB20-AAAB-4262-BC8C-21D2E2E578E2

P478

Q33944184-11955669-2597-42C3-B608-23686D943D3F

P577

Q33944184-8ED1EE43-7307-4426-8999-1E766857DECE

P5875

Q33944184-D75C0177-7C53-4276-A621-166773C87C7A

P698

Q33944184-7732C750-059A-46B5-ADE7-9E02790BC35F

P921

Q33944184-79082277-FB90-46B8-9AFF-A68615CD46F3

Q33944184-F27C99C2-0224-4ECF-A312-D0CE02DD5BAD

P932

Q33944184-809B0C55-E94F-40C9-B054-63DCEDBA62D6

P356

P1433

P1476

Evidence for a two-stage disability progression in multiple sclerosis

@en

P2093

David Laplaud

http://www.w3.org/2001/XMLSchema#string

Emmanuelle Le Page

http://www.w3.org/2001/XMLSchema#string

Emmanuelle Leray

http://www.w3.org/2001/XMLSchema#string

Gilles Edan

http://www.w3.org/2001/XMLSchema#string

Jacqueline Yaouanq

http://www.w3.org/2001/XMLSchema#string

Joël Oger

http://www.w3.org/2001/XMLSchema#string

Marc Coustans

http://www.w3.org/2001/XMLSchema#string

P2860

Defining the clinical course of multiple sclerosis: Results of an international survey

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

Axonal transection in the lesions of multiple sclerosis

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Impact of multiple sclerosis relapses on progression diminishes with time

New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Effect of relapses on development of residual deficit in multiple sclerosis.

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.

P304

1900-1913

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/BRAIN/AWQ076

http://www.w3.org/2001/XMLSchema#string

P407

P433

Pt 7

http://www.w3.org/2001/XMLSchema#string

P478

133

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43348090

http://www.w3.org/2001/XMLSchema#string

P698

20423930

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

2892936

http://www.w3.org/2001/XMLSchema#string